599 related articles for article (PubMed ID: 29291167)
1. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma.
Said A; Ghufran A
World J Clin Oncol; 2017 Dec; 8(6):429-436. PubMed ID: 29291167
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.
Cholankeril G; Patel R; Khurana S; Satapathy SK
World J Hepatol; 2017 Apr; 9(11):533-543. PubMed ID: 28469809
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.
Berkan-Kawińska A; Piekarska A
Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714
[No Abstract] [Full Text] [Related]
6. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
7. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
8. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
9. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Plaz Torres MC; Bodini G; Furnari M; Marabotto E; Zentilin P; Strazzabosco M; Giannini EG
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486355
[TBL] [Abstract][Full Text] [Related]
10. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
[TBL] [Abstract][Full Text] [Related]
11. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
12. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
13. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
14. From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention.
Motta BM; Masarone M; Torre P; Persico M
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001718
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review.
Eguchi Y; Wong G; Lee EI; Akhtar O; Lopes R; Sumida Y
JGH Open; 2020 Oct; 4(5):808-817. PubMed ID: 33102749
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works.
Eguchi Y; Wong G; Lee IH; Akhtar O; Lopes R; Sumida Y
Hepatol Res; 2021 Jan; 51(1):19-30. PubMed ID: 33091191
[TBL] [Abstract][Full Text] [Related]
19. Murine models provide insight to the development of non-alcoholic fatty liver disease.
Reid DT; Eksteen B
Nutr Res Rev; 2015 Dec; 28(2):133-142. PubMed ID: 26494024
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and natural history of patients with NAFLD.
Bhala N; Younes R; Bugianesi E
Curr Pharm Des; 2013; 19(29):5169-76. PubMed ID: 23394091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
